The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Coryell, W.
* Articles by Schlesser, M.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Coryell, W.
* Articles by Schlesser, M.
Related Collections
* Depression
* Other Diagnostic Tools
* Suicide
Am J Psychiatry 158:748-753, May 2001
© 2001 American Psychiatric Association


Article

The Dexamethasone Suppression Test and Suicide Prediction

William Coryell, M.D., and Michael Schlesser, M.D.

OBJECTIVE: Despite the substantial risks of eventual suicide associated with major depressive disorder, clinicians lack robust predictors with which to quantify these risks. This study compared the validity of demographic and historical risk factors with that of the dexamethasone suppression test (DST), a clinically practical measure of hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis. METHOD: Seventy-eight inpatients with Research Diagnostic Criteria major depressive disorder or schizoaffective disorder, depressed type, entered a long-term follow-up study between 1978 and 1981, and, in addition, underwent a 1-mg DST. The number of suicides in this group during a 15-year follow-up period was determined, and the predictive validity of four demographic and historical risk factors reported in the literature to be consistently predictive of suicide in depressed patients was compared to the predictive validity of the DST results. RESULTS: Thirty-two of the 78 patients had abnormal DST results. Survival analyses showed that the estimated risk for eventual suicide in this group was 26.8%, compared to only 2.9% among patients who had normal DST results. None of the demographic and historical risk factors examined in the study significantly distinguished those who later committed suicide from those who did not. CONCLUSIONS: In efforts to predict and prevent suicidal behavior in patients with major depressive disorder, HPA-axis hyperactivity, as reflected in DST results, may provide a tool that is considerably more powerful than the clinical predictors currently in use. Research on the pathophysiology of suicidal behavior in major depressive disorder should emphasize the HPA axis and its interplay with the serotonin system.




This article has been cited by other articles:


Home page
Psychosom. Med.Home page
C. F. Gillespie and C. B. Nemeroff
Hypercortisolemia and Depression
Psychosom Med, May 1, 2005; 67(Supplement_1): S26 - S28.
[Abstract] [Full Text] [PDF]


Home page
FocusHome page
J. K. Schulman, P. R. Muskin, and P. A. Shapiro
Psychiatry and Cardiovascular Disease
Focus, April 1, 2005; 3(2): 208 - 224.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
M. VYTHILINGAM and J. C. NELSON
Drs. Vythilingam and Nelson Reply
Am J Psychiatry, April 1, 2004; 161(4): 765 - 766.
[Full Text]


Home page
Am. J. PsychiatryHome page
M. Vythilingam, J. Chen, J. D. Bremner, C. M. Mazure, P. K. Maciejewski, and J. C. Nelson
Psychotic Depression and Mortality
Am J Psychiatry, March 1, 2003; 160(3): 574 - 576.
[Abstract] [Full Text] [PDF]


Home page
AJGPHome page
B. G. Pollock
Biomarkers: From Bedside to Bench and Back Again
Am J Geriatr Psychiatry, December 1, 2002; 10(6): 644 - 645.
[Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org